1.005
price down icon1.47%   -0.015
 
loading
Precedente Chiudi:
$1.02
Aprire:
$1.02
Volume 24 ore:
104.02K
Relative Volume:
0.51
Capitalizzazione di mercato:
$59.96M
Reddito:
$8.38M
Utile/perdita netta:
$-27.19M
Rapporto P/E:
-0.922
EPS:
-1.09
Flusso di cassa netto:
$-13.59M
1 W Prestazione:
-1.47%
1M Prestazione:
+16.77%
6M Prestazione:
-4.29%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$0.9973
$1.03
Intervallo di 1 settimana:
Value
$0.9606
$1.03
Portata 52W:
Value
$0.65
$1.56

Opus Genetics Inc Stock (IRD) Company Profile

Name
Nome
Opus Genetics Inc
Name
Telefono
248-681-9815
Name
Indirizzo
8 DAVIS DRIVE, DURHAM
Name
Dipendente
18
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
IRD's Discussions on Twitter

Confronta IRD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IRD
Opus Genetics Inc
1.005 60.85M 8.38M -27.19M -13.59M -1.09
Biotechnology icon
ONC
Beigene Ltd Adr
240.41 25.57B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.10 111.79B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 39.90M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
591.85 65.28B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.93 6.31B 0 -153.72M -103.81M -2.00

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-11 Iniziato Craig Hallum Buy
2024-11-13 Ripresa H.C. Wainwright Buy

Opus Genetics Inc Borsa (IRD) Ultime notizie

pulisher
May 19, 2025

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st

May 19, 2025
pulisher
May 18, 2025

Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

May 18, 2025
pulisher
May 16, 2025

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 16, 2025
pulisher
May 16, 2025

Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 15, 2025

Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus

May 15, 2025
pulisher
May 15, 2025

IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView

May 15, 2025
pulisher
May 15, 2025

Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan

May 15, 2025
pulisher
May 12, 2025

Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire

May 12, 2025
pulisher
May 07, 2025

FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

FDA grants Opus Genetics RMAT status for eye therapy - Investing.com

May 06, 2025
pulisher
May 06, 2025

Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times

May 06, 2025
pulisher
May 06, 2025

FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan

May 05, 2025
pulisher
May 02, 2025

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Opus Genetics shareholders approve key proposals - Investing.com

May 01, 2025
pulisher
Apr 28, 2025

Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com

Apr 28, 2025
pulisher
Apr 15, 2025

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 14, 2025

Opus Genetics (NASDAQ:IRD) Research Coverage Started at Craig Hallum - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

Opus Genetics (IRD) Receives Buy Rating with Promising Gene Ther - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - The Manila Times

Apr 12, 2025
pulisher
Apr 11, 2025

Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit Business

Apr 11, 2025
pulisher
Apr 11, 2025

Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq

Apr 11, 2025
pulisher
Apr 11, 2025

Mina Sooch Issues Open Letter To Opus Genetics' Stockholders - marketscreener.com

Apr 11, 2025
pulisher
Apr 10, 2025

Night Vision Disturbances Market to Reach New Heights in Growth - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail

Apr 10, 2025
pulisher
Apr 09, 2025

Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board - MarketScreener

Apr 09, 2025

Opus Genetics Inc Azioni (IRD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$285.56
price down icon 1.56%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Capitalizzazione:     |  Volume (24 ore):